Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an ...

Intestinal failure is defined as having an intestinal condition which renders a child unable to maintain adequate hydration and meet calorie absorption needs sufficient for growth. This results in ...

There were no studies that specifically studied the effect of enteral lipids in infants at risk of liver disease or who have liver disease due to prolonged need for artificial nutrition secondary to ...

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in ...

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

The terms "intestinal barrier" and "intestinal permeability" describe two different aspects of the same anatomical structure, the intestinal wall composed of four layers, the mucosa, the submucosa, ...

SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and ...